Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Journal of the National Cancer Institute
Tamoxifen chemoprevention associated with earlier diagnosis of ER-negative breast cancer
October 23rd, 2008
Women at elevated risk of breast cancer who had been randomly assigned to tamoxifen treatment and then developed estrogen receptor (ER)–negative breast cancer were diagnosed earlier than women who had been randomly assigned to take a placebo and then developed ER-negative disease, according to a study published online October 7 in the Journal of the National Cancer Institute. Tamoxifen has been shown to reduce the risk of ER-positive breast cancer in women at high risk of disease. The drug does not alter the risk of ER-negative disease. In the current study, Yu Shen, Ph.D., of the University of Texas M. D. Anderson Cancer Center in Houston and...
Source: Women's Health Weekly (2008-10-23)
|
